(Q45218584)

10 December 2017

Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction (English)

1 reference

10 December 2017

1 reference

1

1 reference

10 December 2017

2

1 reference

10 December 2017

8

1 reference

10 December 2017

Peter Bie

3

1 reference

10 December 2017

Erling Bjerregaard Pedersen

4

1 reference

10 December 2017

Kaare Troels Jensen

5

1 reference

10 December 2017

Ulrik Abildgaard

6

1 reference

10 December 2017

Birger Hesse

7

1 reference

10 December 2017

1 January 2005

1 reference

European Journal of Heart Failure

10 December 2017

1 reference

10 December 2017

7

1 reference

10 December 2017

1

1 reference

10 December 2017

87-93

1 reference

Risk factors for doxorubicin-induced congestive heart failure

10 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Stress tests and myocardial perfusion scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Plasma endothelin-1 and doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Elevated B-type natriuretic peptide levels after anthracycline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Central venous pressure--a physiological stimulus for secretion of atrial natriuretic peptide in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2004.03.009

10.1016/J.EJHEART.2004.03.009

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference